Acurx Pharmaceuticals stockholders approve officer exculpation amendment and reelect directors at annual meeting

At the Annual Meeting of Acurx Pharmaceuticals, Inc. (“we”, “us” and “our”) held on June 15, 2023 (the “Annual Meeting”), our stockholders approved an amendment to our Certificate of Incorporation, as described in Proposal 3 of our definitive Proxy Statement filed with the Securities and Exchange Commission on April 27, 2023 (the “Proxy Statement”), and which had previously been approved by our Board of Directors subject to stockholder approval. On June 20, 2023, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment of Certificate of Incorporation, the form of which was included as Appendix A to the definitive Proxy Statement.

Proposal 2 - Ratification of Independent Registered Public Accounting Firm Our stockholders ratified the appointment of CohnReznick LLP as our independent auditors for the fiscal year ending December 31, 2023 by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 9,016,668 17,184 64,629 -

Proposal 3 - Amendment to Our Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation The amendment of our Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation was approved by an affirmative vote of a majority of the shares of common stock outstanding and entitled to vote at the Annual Meeting by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 6,054,547 81,822 31,430 2,930,682

Proposal 1 - Election of Directors Our stockholders elected the following directors as Class II directors to hold office until the 2026 Annual Meeting of stockholders by the following votes: Nominees Shares Voted For Shares Withheld Broker Non-Votes David P. Luci 5,749,190 418,609 2,930,682 Jack H. Dean 5,575,112 592,687 2,930,682